+

TNSN98199A1 - Composes therapeutiquement actifs bases sur le remplacement bio- isosterique du catechol par l'indazole dans des inhibiteurs de pde4, leur procede de production et composition pharmaceutique les contenant - Google Patents

Composes therapeutiquement actifs bases sur le remplacement bio- isosterique du catechol par l'indazole dans des inhibiteurs de pde4, leur procede de production et composition pharmaceutique les contenant

Info

Publication number
TNSN98199A1
TNSN98199A1 TNTNSN98199A TNSN98199A TNSN98199A1 TN SN98199 A1 TNSN98199 A1 TN SN98199A1 TN TNSN98199 A TNTNSN98199 A TN TNSN98199A TN SN98199 A TNSN98199 A TN SN98199A TN SN98199 A1 TNSN98199 A1 TN SN98199A1
Authority
TN
Tunisia
Prior art keywords
indazole
catechol
therapeutically active
pharmaceutical composition
production method
Prior art date
Application number
TNTNSN98199A
Other languages
English (en)
Inventor
Marfat Anthony
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN98199A1 publication Critical patent/TNSN98199A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS DE MATIERES THERAPEUTIQUEMENT ACTIVES QUI SONT UTILES DANS LE TRAITEMENT OU LA PREVENTION DE PATHOLOGIES ET AFFECTIONS COMPRENANT DES MALADIES INFLAMMATOIRES, DES MALADIES RESPIRATOIRES ET DES MALADIES INFECTIEUSES ; CETTE COMPOSITION DE MATIERE COMPREND UN COMPOSE DE FORMULE IA ; IB QUI EST INHIBITEUR DE L'ISOZYME PHOSPHODIESTERASE-4 (PDE4) ET DONT LA STRUCTURE CHIMIQUE GLOBALE A UN INDAZOLE COMME COMPOSANT ESSENTIEL, CET INDAZOLE CONSTITUANT UN REMPLACEMENT BIO-ISOSTERIQUE D'UN CATECHOL OU D'UN DERIVE FONCTIONNEL DE CATECHOL DANS UN COMPOSE CONNU DE MEME ACTIVITE THERAPEUTIQUE ET AYANT LES MEMES COMPOSANTS RESTANTS DANS SA STRUCTURE CHIMIQUE GLOBALE ; L'INVENTION CONCERNE AUSSI UN PROCEDE DE PREPARATION DE CES COMPOSITIONS DE MATIERE, ET DES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
TNTNSN98199A 1997-11-04 1998-11-03 Composes therapeutiquement actifs bases sur le remplacement bio- isosterique du catechol par l'indazole dans des inhibiteurs de pde4, leur procede de production et composition pharmaceutique les contenant TNSN98199A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6416097P 1997-11-04 1997-11-04

Publications (1)

Publication Number Publication Date
TNSN98199A1 true TNSN98199A1 (fr) 2005-03-15

Family

ID=22053970

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98199A TNSN98199A1 (fr) 1997-11-04 1998-11-03 Composes therapeutiquement actifs bases sur le remplacement bio- isosterique du catechol par l'indazole dans des inhibiteurs de pde4, leur procede de production et composition pharmaceutique les contenant

Country Status (34)

Country Link
US (2) US6716978B2 (fr)
EP (1) EP1040100A1 (fr)
JP (1) JP2001521925A (fr)
KR (1) KR20010031783A (fr)
CN (1) CN1281441A (fr)
AP (1) AP1122A (fr)
AR (1) AR016413A1 (fr)
AU (1) AU754184B2 (fr)
BG (1) BG104391A (fr)
BR (1) BR9813938A (fr)
CA (1) CA2309175A1 (fr)
CZ (1) CZ20001623A3 (fr)
DZ (1) DZ2639A1 (fr)
EA (1) EA200000385A1 (fr)
HN (1) HN1998000172A (fr)
HR (1) HRP20000262A2 (fr)
HU (1) HUP0100330A3 (fr)
ID (1) ID24942A (fr)
IL (1) IL135714A0 (fr)
IS (1) IS5452A (fr)
MA (1) MA26562A1 (fr)
NO (1) NO20002127L (fr)
NZ (1) NZ503995A (fr)
OA (1) OA11353A (fr)
PA (1) PA8462601A1 (fr)
PE (1) PE131099A1 (fr)
PL (1) PL340799A1 (fr)
SK (1) SK6262000A3 (fr)
TN (1) TNSN98199A1 (fr)
TR (1) TR200001256T2 (fr)
UY (1) UY25232A1 (fr)
WO (1) WO1999023076A1 (fr)
YU (1) YU25400A (fr)
ZA (1) ZA9810042B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
HUP0004150A3 (en) * 1997-11-04 2001-08-28 Pfizer Prod Inc Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
WO2002094320A1 (fr) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions therapeutiques permettant de reparer la chondropathie
US20060079540A1 (en) * 2002-11-27 2006-04-13 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
SI2589599T1 (sl) * 2004-03-03 2014-10-30 Takeda Gmbh Novi hidroksi-6-heteroarilfenantridini in njihova uporaba kot PDE4 inhibitorji
EP1799673A1 (fr) * 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Derives de pyrazole utilises en tant qu'inhibiteurs de phosphodiesterase 4
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
WO2007029077A1 (fr) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Indazoles substitues utilises en tant qu'inhibiteurs de phosphodiesterase de type-iv
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
CN101370775A (zh) 2006-01-13 2009-02-18 惠氏公司 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚
US8044083B2 (en) 2006-01-31 2011-10-25 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
KR101568884B1 (ko) 2007-03-14 2015-11-12 랜박시 래보러터리스 리미티드 포스포디에스테라제 저해제로서 피라졸로 (３,４-ｂ) 피리딘 유도체
WO2009067597A1 (fr) * 2007-11-21 2009-05-28 Decode Genetics Ehf Dérivés de catéchols substitués en position 4 (ou 5)
JP5216912B2 (ja) 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物
CA2722811C (fr) * 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Composes de pyrazole comme antagonistes de ccr1
PE20110854A1 (es) 2008-09-26 2011-12-23 Boehringer Ingelheim Int DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
RS53130B (en) 2009-10-21 2014-06-30 Boehringer Ingelheim International Gmbh INDASOL AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
WO2011056440A1 (fr) 2009-10-27 2011-05-12 Boehringer Ingelheim International Gmbh Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1
EP2509952A1 (fr) * 2009-12-08 2012-10-17 Boehringer Ingelheim International GmbH Procédé de synthèse d'intermédiaires utiles pour la fabrication de for composés à substitution indazole et aza-indazole
UA107818C2 (en) * 2009-12-23 2015-02-25 Medicis Pharmaceutical Corp Usa Alkyl amino pyrimidine derivatives as antagonists district h4-histamine receptors
EP2563787B1 (fr) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Composés azaindazole amides en tant qu'antagonistes des récepteurs ccr1
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
RS57732B1 (sr) 2014-07-15 2018-12-31 Gruenenthal Gmbh Supstituisani derivati azaspiro(4.5)dekana
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
IL312059A (en) 2018-11-19 2024-06-01 Biora Therapeutics Inc Methods and devices for treating a disease with biotherapeutics
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11457370B2 (en) 2020-12-11 2022-09-27 Hewlett Packard Enterprise Development Lp System and method for seamless live upgrade of access points using neighbor data
IL304014A (en) 2020-12-30 2023-08-01 Tyra Biosciences Inc Indazole compounds as kinase inhibitors
CN116003325B (zh) * 2023-01-09 2025-04-25 南方医科大学 吲唑类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064304A1 (de) * 1970-12-29 1972-07-20 Agfa-Gevaert Ag, 5090 Leverkusen Lichtempfindliches farbfotografisches Material
RU2084223C1 (ru) * 1990-05-18 1997-07-20 Хехст АГ Применение амидов изоказол-4-карбоновой кислоты и амидов гидроксиалкилиденциануксусной кислоты
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
TR199802685T2 (xx) * 1996-06-25 1999-03-22 Pfizer Inc �kameli/katk�l� indazol t�revleri
DE69709493T2 (de) * 1996-06-27 2002-10-31 Pfizer Inc., New York Substituierte Indazolderivate
KR100338610B1 (ko) * 1996-09-04 2002-05-27 디. 제이. 우드, 스피겔 알렌 제이 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도
DK0983249T3 (da) * 1997-05-08 2002-07-08 Pfizer Prod Inc Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
HUP0004150A3 (en) * 1997-11-04 2001-08-28 Pfizer Prod Inc Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
OA11353A (en) 2003-12-19
NZ503995A (en) 2003-02-28
HN1998000172A (es) 1999-01-08
EP1040100A1 (fr) 2000-10-04
NO20002127D0 (no) 2000-04-26
US20030158189A1 (en) 2003-08-21
US20020058687A1 (en) 2002-05-16
ZA9810042B (en) 2000-05-03
CA2309175A1 (fr) 1999-05-14
UY25232A1 (es) 2000-12-29
HRP20000262A2 (en) 2000-10-31
CZ20001623A3 (cs) 2001-08-15
DZ2639A1 (fr) 2003-03-08
AP9801376A0 (en) 1998-12-31
ID24942A (id) 2000-08-31
AP1122A (en) 2002-11-29
HUP0100330A3 (en) 2002-03-28
KR20010031783A (ko) 2001-04-16
SK6262000A3 (en) 2002-03-05
AU754184B2 (en) 2002-11-07
WO1999023076A1 (fr) 1999-05-14
PE131099A1 (es) 1999-12-17
TR200001256T2 (tr) 2000-11-21
JP2001521925A (ja) 2001-11-13
BR9813938A (pt) 2000-09-26
YU25400A (sh) 2003-07-07
HUP0100330A2 (hu) 2002-02-28
CN1281441A (zh) 2001-01-24
MA26562A1 (fr) 2004-12-20
BG104391A (en) 2000-12-29
PL340799A1 (en) 2001-02-26
US6716978B2 (en) 2004-04-06
AU9277798A (en) 1999-05-24
PA8462601A1 (es) 2000-05-24
IL135714A0 (en) 2001-05-20
AR016413A1 (es) 2001-07-04
NO20002127L (no) 2000-07-03
EA200000385A1 (ru) 2000-10-30
IS5452A (is) 2000-04-14

Similar Documents

Publication Publication Date Title
TNSN98199A1 (fr) Composes therapeutiquement actifs bases sur le remplacement bio- isosterique du catechol par l'indazole dans des inhibiteurs de pde4, leur procede de production et composition pharmaceutique les contenant
US6150415A (en) Epoxide hydrolase complexes and methods therewith
KR101107949B1 (ko) 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도
DE69513976T2 (de) Entzündungshemmende verbindungen
JP3887020B2 (ja) アズレニルニトロンスピントラッピング剤、ならびにその製造方法および使用方法
EP0954303B1 (fr) Methodes pour traiter les maladies mentales, l'inflammation et la douleur
RU2543720C2 (ru) Композиции для лечения воспаления и способы лечения воспаления
DE69930619T2 (de) Verwendung von rosmarinsäure und deren derivate als immunsuppressor oder als inhibitor von sh-2 vermittelten prozessen
TNSN98200A1 (fr) Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol leur preparation et composition pharmaceutique les contenant
TN2009000138A1 (fr) Biaryl-ether-urees
US20060035869A1 (en) Inhibitors of epoxide hydrolases for the treatment of hypertension
JPH08506344A (ja) アデノシンモノホスフェートデアミナーゼの新規阻害剤
BE895724A (fr) Nouvelle utilisation therapeutique de la dihydrocyclosporine d
FR2502153A1 (fr) Acides (2-oxo-3-tetrahydrothienylcarbamoyl)-alkylthio) acetiques, leurs sels et leurs esters, leur procede de preparation et les compositions pharmaceutiques en contenant
US4605669A (en) Lipoxygenase inhibiting naphthohydroxamic acids
JP2514163B2 (ja) ピリミドン誘導体及び類似化合物を含有する、喘息又は炎症性気道疾患の治療用医薬組成物
DE69818698T2 (de) Inhibitoren von metalloproteinasen, ihre therapeutische verwendung und verfahren zur herstellung der grundstoffe für ihre synthese
Rosenberg et al. Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action
EP0723969A1 (fr) Dérivés de l'acide phosphonocarboxylique et leur utilisation dans le traitement de maladies dégénératives des articulations
CS176291A3 (en) Pharmaceutical
EP0190684B1 (fr) Amides bicycloalkyl, tricycloalkyl, azabicycloalkyl et azatricycloalkyl
JPH0678230B2 (ja) 好中球によるエラスターゼの遊離の阻害剤としてのテニダップ
US5641762A (en) Bone targeted inhibitors of carbonic anhydrase
Bach Lipid mediators of hypersensitivity
CA2158663A1 (fr) Derives du perhydroisoindole, leur preparation et compositions pharmaceutiques en contenant
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载